Lipka AF[au] - Search Results

Year	Number of Results
2009	1
2012	1
2013	2
2014	2
2015	4
2016	2
2017	4
2018	1
2019	1
2020	3
2021	1
2022	1
2023	0

1

Enrichment of serum IgG4 in MuSK myasthenia gravis patients.

Vergoossen DLE, Ruiter AM, Keene KR, Niks EH, Tannemaat MR, Strijbos E, Lipka AF, van der Zijde ECJ, van Tol MJD, Bakker JA, Wevers BA, Westerberg E, Borges LS, Tong OC, Richman DP, Illa I, Punga AR, Evoli A, van der Maarel SM, Verschuuren JJ, Huijbers MG. Vergoossen DLE, et al. Among authors: lipka af. J Neuroimmunol. 2022 Dec 15;373:577978. doi: 10.1016/j.jneuroim.2022.577978. Epub 2022 Oct 7. J Neuroimmunol. 2022. PMID: 36240543 Free article.

2

SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma.

Lipka AF, Verschuuren JJ, Titulaer MJ. Lipka AF, et al. Ann N Y Acad Sci. 2012 Dec;1275:70-7. doi: 10.1111/j.1749-6632.2012.06772.x. Ann N Y Acad Sci. 2012. PMID: 23278580 Review.

3

Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis.

Huijbers MG, Lipka AF, Plomp JJ, Niks EH, van der Maarel SM, Verschuuren JJ. Huijbers MG, et al. Among authors: lipka af. J Intern Med. 2014 Jan;275(1):12-26. doi: 10.1111/joim.12163. Epub 2013 Nov 29. J Intern Med. 2014. PMID: 24215230 Free article. Review.

4

Ephedrine treatment for autoimmune myasthenia gravis.

Lipka AF, Vrinten C, van Zwet EW, Schimmel KJ, Cornel MC, Kuijpers MR, Hekster YA, Weinreich SS, Verschuuren JJ. Lipka AF, et al. Neuromuscul Disord. 2017 Mar;27(3):259-265. doi: 10.1016/j.nmd.2016.11.009. Epub 2016 Nov 18. Neuromuscul Disord. 2017. PMID: 28007405 Free article. Clinical Trial.

5

Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort.

Maddison P, Lipka AF, Gozzard P, Sadalage G, Ambrose PA, Lang B, Verschuuren JJ. Maddison P, et al. Among authors: lipka af. Sci Rep. 2020 Jun 29;10(1):10546. doi: 10.1038/s41598-020-67571-9. Sci Rep. 2020. PMID: 32601396 Free PMC article.

6

Activity limitations in myasthenia gravis and relation to clinical variables.

De Meel RHP, Lipka AF, Van Der Lende M, Van Zwet EW, Tannemaat MR, Verschuuren JJGM. De Meel RHP, et al. Among authors: lipka af. Muscle Nerve. 2017 Jul;56(1):64-70. doi: 10.1002/mus.25463. Epub 2016 Dec 2. Muscle Nerve. 2017. PMID: 27859371

7

Accuracy of patient-reported data for an online patient registry of autoimmune myasthenia gravis and Lambert-Eaton myasthenic syndrome.

Ruiter AM, Strijbos E, de Meel RHP, Lipka AF, Raadsheer WF, Tannemaat MR, Verschuuren JJGM. Ruiter AM, et al. Among authors: lipka af. Neuromuscul Disord. 2021 Jul;31(7):622-632. doi: 10.1016/j.nmd.2021.05.006. Epub 2021 May 29. Neuromuscul Disord. 2021. PMID: 34210541 Free article.

8

Lowering the cutoff value for increment increases the sensitivity for the diagnosis of Lambert-Eaton myasthenic syndrome.

Lipka AF, Titulaer MJ, Tannemaat MR, Verschuuren JJGM. Lipka AF, et al. Muscle Nerve. 2020 Jul;62(1):111-114. doi: 10.1002/mus.26885. Epub 2020 Apr 22. Muscle Nerve. 2020. PMID: 32291768 Free PMC article.

9

Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome.

Huijbers MG, Lipka AF, Potman M, Hensbergen PJ, Titulaer MJ, Niks EH, van der Maarel SM, Klooster R, Verschuuren JJ. Huijbers MG, et al. Among authors: lipka af. Hum Immunol. 2013 Jul;74(7):849-51. doi: 10.1016/j.humimm.2013.03.004. Epub 2013 Apr 10. Hum Immunol. 2013. PMID: 23583364

10

Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome.

Lipka AF, Boldingh MI, van Zwet EW, Schreurs MWJ, Kuks JBM, Tallaksen CM, Titulaer MJ, Verschuuren JJGM. Lipka AF, et al. Neurology. 2020 Feb 4;94(5):e511-e520. doi: 10.1212/WNL.0000000000008747. Epub 2019 Dec 12. Neurology. 2020. PMID: 31831596 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results